Today is the anniversary of Eli Lilly lighting the fuse on the 340B program’s most explosive year ever.
On May 18, 2020, Lilly sent the U.S. Health Resources and Services Administration (HRSA) a letter saying that, unless it heard otherwise by June 30, it would assume it had HRSA’s blessing to stop offering 340B pricing on Cialis dispensed by covered entities’ contract pharmacies, starting July 1. If an entity didn’t have in-house pharmacy, Lilly said the entity could designate just one contract pharmacy for Cialis shipments.
Today is the anniversary of Eli Lilly lighting the fuse on the 340B program’s most explosive year ever.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.